Zomedica Corp Stock Price, News & Analysis

Zomedica Corp. (OTCQB:ZOMDF) has announced the launch of a new monthly webinar series called "Fourth Friday at Four" starting May 23rd, 2025. The series aims to showcase the company's innovative veterinary health products and technologies to investors, veterinarians, and industry partners.

The webinars will highlight Zomedica's product portfolio including the PulseVet® Shock Wave system for musculoskeletal healing, Assisi Loop® and Calmer Canine for pain management and anxiety, TRUFORMA® diagnostic platform, TRUVIEW® Digital Cytology System, VETGuardian® monitoring system, and VETIGEL® hemostatic gel. CEO Larry Heaton emphasized that the series will focus on building a community of professionals while providing insights into the company's technologies and growth strategy.

Zomedica (OTCQB:ZOMDF) has launched the Equine Asthma Clinical Registry, a groundbreaking program utilizing PulseVet® shock wave therapy as a non-invasive, drug-free treatment for equine asthma. The initiative aims to gather real-world clinical evidence on the effectiveness of electrohydraulic extracorporeal shock wave therapy (ESWT) in treating respiratory conditions in horses.

Initial studies show promising results, with 58 horses completing treatment without adverse events. The registry allows veterinary clinics to enroll up to 20 horses, requiring three scheduled visits over 4-6 weeks. Equine asthma affects approximately 15% of horses over age seven, impacting their performance and quality of life. The program offers participating clinics product credits while contributing to vital research in advancing equine respiratory care.

Zomedica Corp (NYSE American:ZOM) announced its delisting from the NYSE American exchange and transition to the OTCQB Venture Market, effective March 5, 2025. The company's ticker symbol will change to ZOMDF.

The delisting is due to the NYSE American's determination that Zomedica no longer meets listing requirements under Section 1003(f)(v) of the Company Guide, specifically citing the low selling price of common shares. Despite this change, Zomedica will maintain SEC reporting requirements and continue providing real-time trading data and financial disclosures through OTC Markets.

CEO Larry Heaton emphasized that while disappointed with the delisting, the company's asset value and growth opportunities remain unchanged, with continued focus on developing veterinary products and maintaining investor engagement.

Zomedica (NYSE American:ZOM) has scheduled its Fourth Quarter and Full Year 2024 Financial Results conference call and audio webcast for March 13, 2025, at 4:30 p.m. ET. The veterinary health company, which specializes in point-of-care diagnostic and therapeutic products for equine and companion animals, will present operational and financial highlights followed by a Q&A session.

Interested participants can join via phone at +1-800-717-1738 (U.S. Toll-Free) or +1-646-307-1865 (International). A replay will be available until March 27, 2025, at 11:59 PM ET by dialing +1-844-512-2921 (U.S. Toll-Free) or +1-412-317-6671 (International) with pin number: 1174148.

Zomedica (NYSE American:ZOM) has relocated its corporate headquarters within Ann Arbor, Michigan, marking a strategic move to improve operational efficiency and reduce costs. The new facility, which replaced their previous Phoenix Drive location after its lease expired on January 31, 2025, represents a 19% reduction in square footage and a 50% reduction in base annual rent.

This relocation is expected to generate over $200,000 in annual cost savings while providing a modernized workspace for the company's growing team. According to management, the move aligns with Zomedica's strategy to achieve profitability by optimizing resources while maintaining investment in innovation and growth. The freed-up capital will be reinvested into the business to accelerate the company's path to financial sustainability.

Zomedica (NYSE:ZOM) has announced a significant update to its endogenous ACTH (eACTH) assay for equine plasma on the TRUFORMA biosensor platform. The enhanced test, initially launched in September 2024, now measures both full-length endogenous ACTH and CLIP (Corticotropin-Like Intermediate Peptide), providing a composite value comparable to traditional laboratory results.

The advancement represents a potential breakthrough in diagnosing Pituitary Pars Intermedia Dysfunction (PPID), a common equine endocrine disorder. The updated assay is particularly notable as it's the first to enable simultaneous measurement of both CLIP and full-length ACTH in a clinical setting, offering veterinarians a more comprehensive diagnostic tool at the point-of-care.

Zomedica (NYSE American:ZOM) has entered into a license and supply agreement with Cresilon Inc. for the Vetigel® hemostatic gel product line. The agreement grants Zomedica exclusive marketing and sales rights in the United States and non-exclusive rights internationally.

Vetigel is a plant-based formula designed to rapidly stop bleeding when applied directly to wounds. The product has been clinically validated for multiple applications, including surgical procedures, dental applications, emergency care, and liver biopsies. Key advantages include its ability to stop bleeding in seconds without becoming part of the clot.

Under the agreement, Zomedica will manage U.S. customer supply and collaborate with Cresilon for international customer support. The company plans to leverage its existing field sales team, trade show programs, and continuing education initiatives to expand Vetigel's market presence.

Zomedica (NYSE American:ZOM) has launched two new canine assays for its TRUFORMA In-Clinic Biosensor Testing Platform. The first is a canine NT-proBNP test for detecting cardiac conditions, which helps distinguish cardiac from respiratory disease and identifies dogs at risk of congestive heart failure. The second is a progesterone test for determining optimal breeding dates and detecting reproductive disorders.

These additions bring the total to 8 new assays launched in the past 18 months. Both tests deliver quantitative results in under 20 minutes with reference lab accuracy. The NT-proBNP test is particularly significant as 1 in 10 dogs experience heart disease, while the progesterone assay addresses a high demand market with 4 million puppies born annually in the US. Zomedica offers these diagnostics without requiring capital outlay or monthly minimums from veterinary practices.

Zomedica Corp. (NYSE American:ZOM) has appointed Scott A. Jordan as Executive Vice President, Finance and Chief Financial Officer, effective January 1, 2025. Jordan brings over 30 years of experience in life sciences and diagnostics industries. He was previously CEO and Founder of S. Jordan Associates, a Chicago-based boutique investment bank, and CFO of Inomagen Therapeutics. His experience includes roles as Chief Business Officer/CFO at Iterion Therapeutics and Salarius Pharmaceuticals, where he helped achieve NASDAQ listing. Jordan holds a BA in Marketing from Michigan State University and an MBA in Finance from DePaul University. He succeeds Peter Donato, who departed in August 2024.